Dark

TPST
Tempest Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Jun 23, 2025 3:59:51 PM EDT

6.90USD+1.770%(+0.12)37,857

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 23, 2025 8:43:30 AM EDT

6.85USD+1.032%(+0.07)349

After-hours

Jun 23, 2025 4:38:30 PM EDT

6.90USD0.000%(0.00)759

OverviewOptionsHistoricalExchangesShortsNews

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Nov 18, 2021

08:04AM EST Tempest Announces First Patient Dosed With TPST-1495 In Combination With Pembrolizumab Benzinga

08:00AM EST -- Combination based on both strong mechanistic rationale and preclinical data GlobeNewswire Inc

Nov 12, 2021

07:00AM EST -- Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire Inc

Nov 10, 2021

06:22PM EST Tempest Therapeutics Q3 EPS $(1.21) Up From $(11.22) YoY Benzinga

Nov 9, 2021

08:00AM EST Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the following investor conferences in November: GlobeNewswire Inc

Nov 8, 2021

08:00AM EST Tempest Further Bolsters Patent Portfolio with Issuance GlobeNewswire Inc

Oct 21, 2021

12:12PM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2021 Benzinga

12:11PM EDT William Blair Initiates Coverage On Tempest Therapeutics with Outperform Rating Benzinga

Oct 1, 2021

08:06AM EDT Tempest Announces Presentation At Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting On Nov. 10-14 Benzinga

08:00AM EDT Tempest Announces Presentation at the Society for Immunotherapy of GlobeNewswire Inc

Sep 20, 2021

08:03AM EDT Tempest Announces First Patient Dosed In Randomized Study Evaluating TPST-1120 In First-Line Regimen For Hepatocellular Carcinoma In Clinical Collaboration With Roche Benzinga

08:00AM EDT Tempest Announces First Patient Dosed in Randomized Study GlobeNewswire Inc

Sep 13, 2021

08:07AM EDT Tempest Enters Into Exclusive License Agreement With The University Of California For Novel Cancer Target Benzinga

08:00AM EDT Tempest Enters into Exclusive License Agreement with the GlobeNewswire Inc

Sep 9, 2021

04:01PM EDT Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the following investor conferences in September: GlobeNewswire Inc

Aug 12, 2021

04:37PM EDT Tempest Therapeutics Q2 EPS $(7.63) Up From $(11.42) YoY Benzinga

04:01PM EDT -- Closed merger transaction resulting in public listing (TPST) -- Closed $30M PIPE, extending runway into Q123 -- Advancing TPST-1495 and TPST-1120 into targeted patient populations -- Advanced TREX-1 program to potent lead series with in vivo efficacy GlobeNewswire Inc

Aug 9, 2021

08:00AM EDT Tempest Announces Appointment of Ronit Simantov, M.D. to its Board GlobeNewswire Inc

Jul 15, 2021

10:25AM EDT Mid-Morning Market Update: Markets Mostly Lower; Morgan Stanley Tops Q2 Views Benzinga

Jul 13, 2021

10:13AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 Benzinga

09:12AM EDT H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest Therapeutics Benzinga

06:10AM EDT HC Wainwright & Co. Initiates Coverage On Tempest Therapeutics with Buy Rating, Announces Price Target of $51 Benzinga

Jul 12, 2021

12:05PM EDT David Green's Top Trades For Monday: SGOCO, Virgin Galactic, and Palantir Benzinga

10:27AM EDT Mid-Morning Market Update: Markets Mostly Higher; Novo Nordisk To Acquire Prothena's ATTR Amyloidosis Program Benzinga

Jul 9, 2021

08:03AM EDT Tempest to Participate in William Blair 2021 Biotech Focus Conference GlobeNewswire Inc

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 6, 2021

11:01AM EDT Shares of micro-cap Tempest Therapeutics Inc. (TPST) are currently gaining over 13% on Tuesday morning despite no stock-related statement from the clinical stage oncology company. RTTNews

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021 Benzinga

09:22AM EDT Piper Sandler Initiates Coverage On Tempest Therapeutics with Overweight Rating, Announces Price Target of $23 Benzinga

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jul 1, 2021

04:00PM EDT Tempest Therapeutics, Inc. (Nasdaq: TPST) (Tempest), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of 20-year industry veteran Christine Pellizzari to the companys Board of Directors. GlobeNewswire Inc

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

Jun 28, 2021

07:50AM EDT Tempest Closes Merger with Millendo and Completes PIPE Financing GlobeNewswire Inc

.dark-mode .Jyvdck{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .Jyvdck{ color: #333333; background-color: white; border: 2px solid #333333; }TPSTTempest Therapeutics, Inc. Common Stockstock NASDAQ

TPST
Tempest Therapeutics, Inc. Common Stock
stock NASDAQ